海外の治験の状況「1」での検索結果
2657件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Not Recruiting
- Effects of Royal Jelly Supplementation on Regulatory T Cells and Lymphocytes Apoptosis in Children with Systemic Lupus Erythematosus
- Systemic Lupus Erythematosus.
- Africa
- 2016-02-05
Authorised
- A study of the Safety and Effectiveness of Pegylated Recombinant Factor VIII (BAX 855) in Prevention of Bleeding in Patients with Severe Hemophilia A (a blood clotting disorder) using two different dosing schedules to target different levels of BAX855 in the blood.
- Severe hemophilia A (FVIII 1%) MedDRA version: 20.0 Level: LLT Classification code 10060612 Term: Hemophilia A System Organ Class: 100000011915 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Australia, Austria, Bulgaria, Czech Republic, France, Germany, Hong Kong, Hungary, Israel, Italy, Malaysia, Poland, Singapore, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2015-10-12
Authorised
- Phase 1/2 Study to Evaluate the Safety and Efficacy of BMN 250 in Patients with MPS IIIB
- Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B, MPS IIIB) MedDRA version: 20.0 Level: LLT Classification code 10056918 Term: Sanfilippo's syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.1 Level: PT Classification code 10056890 Term: Mucopolysaccharidosis III System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Australia, Colombia, Germany, Spain, Taiwan, Turkey, United Kingdom
- 2015-09-30
Authorised
- A clinical study involving previously untreated patients with haemophilia A to look at how safe an experimental replacement factor VIII protein (known as rFVIIIFc) is to take and how well it works to prevent and stop bleeds.
- Hemophilia A MedDRA version: 20.0 Level: LLT Classification code 10053753 Term: Hemophilia A without inhibitors System Organ Class: 100000004850 MedDRA version: 20.0 Level: LLT Classification code 10060612 Term: Hemophilia A System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Australia, Brazil, Canada, Denmark, France, Germany, Ireland, Italy, Netherlands, New Zealand, Poland, Spain, Sweden, United Kingdom, United States
- 2014-05-06
Recruiting
- A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- Epilepsy, Partial Seizures;Epilepsy, Primary Generalized Tonic-Clonic Seizures
- Argentina, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, China, Croatia, Czech Republic, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Korea, Republic of, Lebanon, Lithuania, Malaysia, Montenegro, Netherlands, Philippines, Poland, Romania, Russian Federation, Serbia, Singapore, Slovakia, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
- 2011-10-17
Recruiting
- A clinical research study testing olaparib, in Homologous recombination (HR) deficient metastatic breast and relapsed ovarian cancer in patients who do not have hereditary mutations in BReast CAncer susceptibility gene 1 and gene 2 (BRCA1 and BRCA2)
- Triple negative breast cancer;High grade serous ovarian cancer
- Australia
- 2017-06-09
Not recruiting
- Testing Effective Strategies for Reducing Child Problem Behavior Among Children Diagnosed with Attention Deficit Hyperactivity Disorder (ADHD): An Evaluation of the 1-2-3 Magic Parenting Program
- Childhood ADHD
- Australia
- 2017-03-16
Not recruiting
- Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
- Dementia;Alzheimer's Disease
- Australia, Canada, South Africa, United States
- 2005-02-24
Not recruiting
- A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents
- HIV-1;HIV Infections
- Argentina, Brazil, Canada, France, Romania, South Africa, Spain, United Kingdom, United States
- 2006-07-21
Not recruiting
- Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Retardation: A Longtitudinal Study
- Prenatal Care;Premature Birth
- Australia, Chile, Italy, Korea, Republic of, United States
- 2006-06-19
Not recruiting
- Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
- Accelerated Phase Chronic Myelogenous Leukemia;Blastic Phase Chronic Myelogenous Leukemia;Childhood Acute Lymphoblastic Leukemia in Remission;Childhood Acute Myeloid Leukemia in Remission;Childhood Chronic Myelogenous Leukemia;Childhood Myelodysplastic Syndromes;Chronic Phase Chronic Myelogenous Leukemia;de Novo Myelodysplastic Syndromes;Disseminated Neuroblastoma;Juvenile Myelomonocytic Leukemia;Previously Treated Childhood Rhabdomyosarcoma;Previously Treated Myelodysplastic Syndromes;Pulmonary Complications;Recurrent Childhood Acute Lymphoblastic Leukemia;Recurrent Childhood Acute Myeloid Leukemia;Recurrent Childhood Large Cell Lymphoma;Recurrent Childhood Lymphoblastic Lymphoma;Recurrent Childhood Rhabdomyosarcoma;Recurrent Childhood Small Noncleaved Cell Lymphoma;Recurrent Neuroblastoma;Recurrent Wilms Tumor and Other Childhood Kidney Tumors;Recurrent/Refractory Childhood Hodgkin Lymphoma;Relapsing Chronic Myelogenous Leukemia;Secondary Acute Myeloid Leukemia;Secondary Myelodysplastic Syndromes;Accelerated Phase Chronic Myelogenous Leukemia;Blastic Phase Chronic Myelogenous Leukemia;Childhood Acute Lymphoblastic Leukemia in Remission;Childhood Acute Myeloid Leukemia in Remission;Childhood Chronic Myelogenous Leukemia;Childhood Myelodysplastic Syndromes;Chronic Phase Chronic Myelogenous Leukemia;de Novo Myelodysplastic Syndromes;Disseminated Neuroblastoma;Juvenile Myelomonocytic Leukemia;Previously Treated Childhood Rhabdomyosarcoma;Previously Treated Myelodysplastic Syndromes;Pulmonary Complications;Recurrent Childhood Acute Lymphoblastic Leukemia;Recurrent Childhood Acute Myeloid Leukemia;Recurrent Childhood Large Cell Lymphoma;Recurrent Childhood Lymphoblastic Lymphoma;Recurrent Childhood Rhabdomyosarcoma;Recurrent Childhood Small Noncleaved Cell Lymphoma;Recurrent Neuroblastoma;Recurrent Wilms Tumor and Other Childhood Kidney Tumors;Recurrent/Refractory Childhood Hodgkin Lymphoma;Relapsing Chronic Myelogenous Leukemia;Secondary Acute Myeloid Leukemia;Secondary Myelodysplastic Syndromes;Accelerated Phase Chronic Myelogenous Leukemia;Blastic Phase Chronic Myelogenous Leukemia;Childhood Acute Lymphoblastic Leukemia in Remission;Childhood Acute Myeloid Leukemia in Remission;Childhood Chronic Myelogenous Leukemia;Childhood Myelodysplastic Syndromes;Chronic Phase Chronic Myelogenous Leukemia;de Novo Myelodysplastic Syndromes;Disseminated Neuroblastoma;Juvenile Myelomonocytic Leukemia;Previously Treated Childhood Rhabdomyosarcoma;Previously Treated Myelodysplastic Syndromes;Pulmonary Complications;Recurrent Childhood Acute Lymphoblastic Leukemia;Recurrent Childhood Acute Myeloid Leukemia;Recurrent Childhood Large Cell Lymphoma;Recurrent Childhood Lymphoblastic Lymphoma;Recurrent Childhood Rhabdomyosarcoma;Recurrent Childhood Small Noncleaved Cell Lymphoma;Recurrent Neuroblastoma;Recurrent Wilms Tumor and Other Childhood Kidney Tumors;Recurrent/Refractory Childhood Hodgkin Lymphoma;Relapsing Chronic Myelogenous Leukemia;Secondary Acute Myeloid Leukemia;Secondary Myelodysplastic Syndromes;Accelerated Phase Chronic Myelogenous Leukemia;Blastic Phase Chronic Myelogenous Leukemia;Childhood Acute Lymphoblastic Leukemia in Remission;Childhood Acute Myeloid Leukemia in Remission;Childhood Chronic Myelogenous Leukemia;Childhood Myelodysplastic Syndromes;Chronic Phase Chronic Myelogenous Leukemia;de Novo Myelodysplastic Syndromes;Disseminated Neuroblastoma;Juvenile Myelomonocytic Leukemia;Previously Treated Childhood Rhabdomyosarcoma;Previously Treated Myelodysplastic Syndromes;Pulmonary Complications;Recurrent Childhood Acute Lymphoblastic Leukemia;Recurrent Childhood Acute Myeloid Leukemia;Recurrent Childhood Large Cell Lymphoma;Recurrent Childhood Lymphoblastic Lymphoma;Recurrent Childhood Rhabdomyosarcoma;Recurrent Childhood Small Noncleaved Cell Lymphoma;Recurrent Neuroblastoma;Recurrent Wilms Tumor and Other Childhood Kidney Tumors;Recurrent/Refractory Childhood Hodgkin Lymphoma;Relapsing Chronic Myelogenous Leukemia;Secondary Acute Myeloid Leukemia;Secondary Myelodysplastic Syndromes
- Australia, Canada, United States
- 2006-03-29
Not Recruiting
- A randomised double blind controlled trial of oral ephedrine/etilefrine in the prevention of recurrent (stuttering) attacks of priapism in sickle cell disease: a multicentre international study in older children and adults
- Sickle cell disease Haematological Disorders Sickle-cell disorders
- Nigeria, United Kingdom
- 2006-02-02
Not Recruiting
- Comparative evaluation of immunogenicity of monovalent type 1 oral poliovirus vaccine (mOPV1) versus trivalent OPV (tOPV): a randomised double-blind trial set in Egypt
- Polio Infections and Infestations Polio
- Egypt
- 2006-02-01
Not recruiting
- Phase 1/2 study of SIR-Spheres plus systemic chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin in patients with liver metastases from colorectal carcinoma
- Unresectable liver metastases from colorectal carcinoma
- Australia
- 2006-01-04
Not recruiting
- A phase 1 multicentre open label dose-escalation study of unrelated, major histocompatibility (MHC)-unmatched mesenchymals stem cells (MSC) for the treatment of steroid refractory acute graft versus host disease in recipients of allogeneic heamatopoietic stem cell transplants
- Patients who have undergone a allogeneic stem cell transplant who have developed steroid refractory graft versus host disease
- Australia
- 2007-08-23
Not recruiting
- CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.
- Asthma
- Australia, Austria, Belgium, Bulgaria, Canada, Estonia, Finland, Germany, Ireland, Latvia, Macedonia, The Former Yugoslav Republic of, Netherlands, New Zealand, Spain, United Kingdom
- 2007-05-25
Recruiting
- Investigation of the effect of a single dose of stimulant medication (dexamphetamine 10mg or methylphenidate 20mg) on appetite and on fasting and postprandial levels of insulin, glucose, leptin and ghrelin in healthy adult volunteers.
- Appetite suppression on stimulant medication. This is the presumed reason for the weight loss that usually occurs when children with attention deficit hyperactivity disorder (ADHD) are treated with dexamphetamine or methylphenidate.;Healthy adult volunteers.
- Australia
- 2007-02-21
Recruiting
- Prospective Study to investigate the ability of the Glutathione S- transferase Pi (GSTP1) methylation assay to assess response to chemotherapy in patients with metastatic hormone-refractory prostate cancer
- Patients with Metastatic hormone-refractory prostate cancer
- Australia
- 2007-01-23
Not recruiting
- Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)
- Diabetes Mellitus, Type 2;Diabetes Mellitus, Type 2;Diabetes Mellitus, Type 2;Diabetes Mellitus, Type 2
- Australia, Austria, Brazil, Chile, Colombia, Costa Rica, Denmark, Finland, France, Germany, Guatemala, Hungary, India, Israel, Italy, Jordan, Korea, Republic of, Lebanon, Malaysia, Mexico, New Zealand, Norway, Peru, Philippines, Russian Federation, Saudi Arabia, South Africa, Sweden, Taiwan, United States
- 2008-10-03
Not Recruiting
- Prospective, randomized, non-blind, comparative with parallel groups, multicenter and multinational phase IH clinical study of the efficacy and safety of moxifloxacin 400 mg od sequential therapy versus amoxicillin/clavulanate 1 g IV tid followed by amoxicillin/clavulanate 625 mg PO tid for the treatment of complicated skin and skin structure infections during a 21-day period (Study 10279)
- -L089 Local infection of skin and subcutaneous tissue, unspecified Local infection of skin and subcutaneous tissue, unspecified;Local infection of skin and subcutaneous tissue, unspecified
- Argentina, Chile, Colombia, Germany, Hungary, Israel, Mexico, Peru, Philippines, South Africa, Spain, Taiwan
- 2001-03-30